U.S. Markets close in 5 hrs 47 mins
  • S&P 500

    3,669.55
    -74.97 (-2.00%)
     
  • Dow 30

    29,455.75
    -471.19 (-1.57%)
     
  • Nasdaq

    10,781.43
    -291.88 (-2.64%)
     
  • Russell 2000

    1,716.91
    -35.60 (-2.03%)
     
  • Crude Oil

    90.11
    +1.66 (+1.88%)
     
  • Gold

    1,703.60
    -17.20 (-1.00%)
     
  • Silver

    20.22
    -0.44 (-2.13%)
     
  • EUR/USD

    0.9755
    -0.0040 (-0.4097%)
     
  • 10-Yr Bond

    3.8900
    +0.0640 (+1.67%)
     
  • Vix

    31.50
    +0.98 (+3.21%)
     
  • GBP/USD

    1.1106
    -0.0063 (-0.5631%)
     
  • USD/JPY

    145.2160
    +0.1480 (+0.1020%)
     
  • BTC-USD

    19,627.77
    -375.55 (-1.88%)
     
  • CMC Crypto 200

    446.87
    -8.16 (-1.79%)
     
  • FTSE 100

    6,975.07
    -22.20 (-0.32%)
     
  • Nikkei 225

    27,116.11
    -195.19 (-0.71%)
     

Arcellx Announces Participation at the Morgan Stanley 20th Annual Global Healthcare Conference

·3 min read

REDWOOD CITY, Calif., Sept. 7, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022, at 3:30 p.m. ET.

Corporate logo (PRNewsfoto/Arcellx, Inc)
Corporate logo (PRNewsfoto/Arcellx, Inc)

A live webcast of the discussion will be accessible from Arcellx's website at www.arcellx.com in the Investor section. A replay of the webcast will be archived and available for 30 days following the event.

About Arcellx, Inc.

Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx's mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx's lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.

Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, expected to enter the clinic in the second half of 2022.

Visit www.arcellx.com for more information.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this press release that are not purely historical are forward-looking statements, including Arcellx's expectations regarding the timing of clinical trials for its product candidates. The forward-looking statements contained herein are based upon Arcellx's current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including those set forth in Part I, Item 1A (Risk Factors) of Arcellx's Annual Report on Form 10-K and in other reports, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, that Arcellx may file from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Arcellx assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact:
Myesha Lacy
Arcellx, Inc.
ir@arcellx.com
510-418-2412

Media Contact

Andrea Cohen
Sam Brown Inc.
andreacohen@sambrown.com
917-209-7163

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/arcellx-announces-participation-at-the-morgan-stanley-20th-annual-global-healthcare-conference-301618712.html

SOURCE Arcellx, Inc